London — GlaxoSmithKline, the world's largest vaccine maker, said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of 2021.

"If things go right … to get to scale of manufacturing in the hundreds of millions (of doses) is going to be in the second half of next year," CEO Emma Walmsley told a media briefing after the release of first-quarter results...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.